摘要
目的:观察和评价西妥昔单抗(爱必妥)联合FOLFIRI方案治疗国人晚期大肠癌患者的疗效及毒副反应。方法:回顾性分析2006年6月～2008年12月我院经病理证实的晚期大肠癌患者43例,爱必妥400mg/m2,第1次;以后250mg/m2,每周1次,或者500mg/m2,每2周1次;伊立替康(开普拓)180mg/m2,第1天,静滴30分钟;亚叶酸钙200mg/m2,第1、2天,静滴2小时;氟尿嘧啶(5-FU)400mg/m2,静推,第1、2天,5-FU600mg/m2,持续静滴22小时,第1、2天,每2周重复。每例至少接受4周期化疗后评价疗效。结果:全组43例均可评价,有效率(CR+PR)为34.9%(15/43),SD 48.8%(21/43),PD16.3%(7/43)。中位疾病进展时间(TTP)8.9个月,中位生存期(OS)19.3个月。治疗相关毒副反应主要为皮疹、迟发性腹泻及中性粒细胞减少。结论:西妥昔单抗联合FOLFIRI方案治疗国人晚期大肠癌疗效肯定,可使大部分患者临床获益,其毒副反应可以耐受。
Objective：To evaluate the efficacy and adverse effects of cetuximab with FOLFIRI regimen for the Chinese advanced colorectal cancer.Methods：From June,2006 to December,2008,retrospective analysis 43 cases advanced colorectal cancer were proved by pathology.Cetuximab was given by 400mg/m2 on day 1 with subsequent weekly doses of 250mg/m2 or 500mg/m2 every 2 weeks.Irinotican was given by 180mg/m2,d1,dripping into vein in 30 minutes;LV 200mg/m2,d1,d2;5-FU 400mg/m2,blous,d1,d2,5-FU 600mg/m2,civ22h,d1,d2,every 2 weeks was a cycle.All the patients recieved at least 4 cycles of chemotherapy.Results：In 43 patients,34.9%（15/43） of response rate was observed and SD was 48.8%（21/43）,PD was 16.3%（7/43）.MST was 19.3months,TTP was 8.9months.The common treatment related adverse events were skin rash,delayed diarrhea and neutropenia.Conclusion：Cetuximab combined with FOLFIRI for the Chinese patients with advanced colorectal cancer is an active regimen.It gives the most patients clinical benifit and its side effects are tolerable.
出处
《临床肿瘤学杂志》
CAS
2009年第10期919-922,共4页
Chinese Clinical Oncology
关键词
大肠癌
西妥昔单抗
伊立替康
氟尿嘧啶
化学治疗
Colorectal carcinoma
Cetuximab
Irinotican （ CPT-11 ）
Fluorouracil （5-FU）
Chemotherapy
